Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn moreAgrova International has acquired Sunrise Eggs
Agrova International, led by its founder Jurijs Adamovičs, has acquired 100 percent of the shares in Sunrise Eggs, a UK-based egg production and distribution company. This acquisition significantly expands Agrova’s operational footprint and strengthens its position as a pan-European player in the egg and egg protein industry. The transaction was supported with funding from Accession Capital Partners (ACP), a growth capital provider with experience in the agriculture sector.
Learn moreSmile Invest has secured debt financing for the acquisition of RB+ Groep
Smile Invest has successfully acquired a majority stake in RB+ Groep, a specialist in comprehensive fire prevention solutions operating under the brands Van der Aa, Firejob and Preficon Europe, with a strong focus on constructional fire prevention. This transaction supports RB+’s growth ambitions and enables the company to expand into adjacent and international markets.
Learn more